These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32615262)

  • 21. Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study.
    Bodensohn R; Kolorz A; Reis J; Werner S; Forbrig R; Garny S; Taugner J; de Colle C; Belka C; Manapov F; von Baumgarten L; Niyazi M
    Transl Lung Cancer Res; 2024 Jul; 13(7):1635-1648. PubMed ID: 39118877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.
    Hall J; Lui K; Tan X; Shumway J; Collichio F; Moschos S; Sengupta S; Chaudhary R; Quinsey C; Jaikumar S; Forbes J; Andaluz N; Zuccarello M; Struve T; Vatner R; Pater L; Breneman J; Weiner A; Wang K; Shen C
    Radiother Oncol; 2023 Dec; 189():109920. PubMed ID: 37769968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
    Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL
    J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
    Tian S; Switchenko JM; Buchwald ZS; Patel PR; Shelton JW; Kahn SE; Pillai RN; Steuer CE; Owonikoko TK; Behera M; Curran WJ; Higgins KA
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):304-313. PubMed ID: 31982496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.
    Johnson MD; Avkshtol V; Baschnagel AM; Meyer K; Ye H; Grills IS; Chen PY; Maitz A; Olson RE; Pieper DR; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):537-43. PubMed ID: 26867883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic radiosurgery for small brain metastases and implications regarding management with systemic therapy alone.
    Trifiletti DM; Hill C; Cohen-Inbar O; Xu Z; Sheehan JP
    J Neurooncol; 2017 Sep; 134(2):289-296. PubMed ID: 28577030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases.
    Lehrer EJ; McGee HM; Sheehan JP; Trifiletti DM
    J Neurooncol; 2021 Jan; 151(1):75-84. PubMed ID: 32052355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiinstitutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases from non-small cell lung cancer (JLGK0901 study-NSCLC).
    Shuto T; Akabane A; Yamamoto M; Serizawa T; Higuchi Y; Sato Y; Kawagishi J; Yamanaka K; Jokura H; Yomo S; Nagano O; Aoyama H
    J Neurosurg; 2018 Dec; 129(Suppl1):86-94. PubMed ID: 30544291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.
    Klausner G; Troussier I; Biau J; Jacob J; Schernberg A; Canova CH; Simon JM; Borius PY; Malouf G; Spano JP; Roupret M; Cornu P; Mazeron JJ; Valéry C; Feuvret L; Maingon P
    Clin Genitourin Cancer; 2019 Jun; 17(3):191-200. PubMed ID: 30926219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of additional brain metastases on the day of stereotactic radiosurgery: risk factors and outcomes.
    Garcia MA; Lazar A; Duriseti S; Raleigh DR; Hess CP; Fogh SE; Barani IJ; Nakamura JL; Larson DA; Theodosopoulos P; McDermott M; Sneed PK; Braunstein S
    J Neurosurg; 2017 Jun; 126(6):1756-1763. PubMed ID: 27367235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases.
    Lehrer EJ; McGee HM; Peterson JL; Vallow L; Ruiz-Garcia H; Zaorsky NG; Sharma S; Trifiletti DM
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follow-up results of brain metastasis patients undergoing repeat Gamma Knife radiosurgery.
    Koiso T; Yamamoto M; Kawabe T; Watanabe S; Sato Y; Higuchi Y; Yamamoto T; Matsumura A; Kasuya H
    J Neurosurg; 2016 Dec; 125(Suppl 1):2-10. PubMed ID: 27903177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant stereotactic radiosurgery for intracerebral metastases of solid tumors (NepoMUC): a phase I dose escalation trial.
    Diehl CD; Shiban E; Straube C; Gempt J; Wilkens JJ; Oechsner M; Kessel C; Zimmer C; Wiestler B; Meyer B; Combs SE
    Cancer Commun (Lond); 2019 Nov; 39(1):73. PubMed ID: 31706337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience.
    Hughes RT; Masters AH; McTyre ER; Farris MK; Chung C; Page BR; Kleinberg LR; Hepel J; Contessa JN; Chiang V; Ruiz J; Watabe K; Su J; Fiveash JB; Braunstein S; Chao S; Attia A; Ayala-Peacock DN; Chan MD
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1091-1098. PubMed ID: 30959122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
    Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.